Cencora, Inc.(COR)
Cencora, Inc. sources and distributes pharmaceutical products. Its U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers. The company also provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; and pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets. In addition, this segment distributes plasma and other blood products, injectable pharmaceuticals, vaccines, and other specialty products; and provides other services primarily to physicians who specialize in various disease states, primarily oncology, as well as to other healthcare providers, including hospitals and dialysis clinics. The company's International Healthcare Solutions segment offers international pharmaceutical wholesale and related service, and global commercialization services; and distributes pharmaceuticals, other healthcare products, and related services to pharmacies, doctors, health centers and hospitals primarily in Europe. This segment also provides specialty transportation and logistics services for the biopharmaceutical industry. The company was formerly known as AmerisourceBergen Corporation and changed its name to Cencora, Inc. in August 2023. Cencora, Inc. was incorporated in 2001 and is headquartered in Conshohocken, Pennsylvania.
Latest News & Analysis
Cencora: Disciplined Capital Returns and Earnings Visibility Drive Re-Rating
Cencora's earnings visibility and capital discipline are driving a market re-rating as specialty channels expand.
Cencora's Strategic Shift: Navigating Drug Demand and Stake Reduction
Cencora navigates specialty drug demand and Walgreens' stake reduction. Q1 earnings, strategic shifts, and market dynamics analyzed for investors and analysts.
Cencora: Navigating Market Shifts and Industry Trends in 2025
A detailed analysis of Cencora's Q1 2025 earnings, share repurchase, and strategic positioning amid Walgreens' stake sale.
Cencora (COR): Walgreens' Stake Reduction, Analyst Outlook & Q1 2025 Analysis
Cencora's (COR) latest developments, including Walgreens' stake reduction, analyst outlook, and Q1 2025 earnings. Impact on financial health and growth prospects is analyzed.
Cencora (COR): Navigating Walgreens' Stake Reduction and Q1 2025 Performance
Analysis of Cencora's (COR) recent developments, including Walgreens' stake reduction, Q1 2025 earnings, and strategic acquisitions. Explores the company's outlook and key success factors.
Cencora (COR): Navigating Change and Charting Future Growth
Cencora (COR) is navigating change as Walgreens reduces its stake. Strong financials, strategic acquisitions, and share repurchases position it for growth.
Cencora (COR): Financial Analysis of Growth and Market Trends
Analysis of Cencora's (COR) stock performance, financial results, Walgreens' reduced stake, and the RCA acquisition. Assesses competitive landscape, valuation, and future outlook.
Cencora (COR) Analysis: Financials, Acquisitions, Market Outlook
In-depth analysis of Cencora (COR): financial performance, strategic acquisitions, and market outlook. Walgreens' stake reduction, RCA deal, and cash conversion cycle.
Cencora (COR): Q2 Earnings Preview, AI Impact, and Growth
Comprehensive analysis of Cencora (COR) focusing on Q2 2025 earnings, AI initiatives, financial sustainability, and market strategies.
Cencora (COR): Riding All-Time Highs Amidst Market Volatility
Cencora (COR) reaches an all-time high amid market volatility, driven by strategic AI adoption, tariff mitigation, and strong financials. Q2 Fiscal 2025 earnings are eagerly awaited.
Cencora (COR): Analyzing Tariff Headwinds and Cash Flow Dynamics
Deep dive into Cencora's recent developments, including tariff impacts, cash flow dynamics, competitive positioning, and analyst sentiment ahead of its Q2 earnings.
Cencora ([COR](/dashboard/companies/COR)) Financial Analysis: Revenue Growth vs. Margin Pressure
Cencora ([COR](/dashboard/companies/COR)) navigates strategic shifts, including international exploration and governance enhancements, against a backdrop of robust revenue growth tempered by margin pressures.
Cencora's Strategic Growth: Specialty Drugs Drive Revenue Surge
Cencora's Q2 fiscal 2025 revenue surged +10.3%, fueled by specialty drugs. New board appointment strengthens supply chain as company navigates margin pressures.
Cencora Q3 Earnings Preview: U.S. Healthcare Solutions Fuel Growth Amid Market Challenges | COR Stock Analysis
Cencora’s Q3 FY2025 earnings preview highlights strong U.S. Healthcare Solutions growth amid competitive pressures and margin headwinds, with raised full-year EPS guidance.
Cencora (COR) Q2 2025 Analysis: Navigating Revenue Growth Amid Margin Pressures
Cencora's Q2 2025 results show revenue growth of +12.12% with margin contraction, reflecting strategic shifts and competitive pressures in healthcare services.
Cencora Q3 FY25 Earnings Beat: Strategic Growth from GLP-1 Demand and Citius Oncology Deal
Cencora (COR) beats Q3 FY25 earnings with strong GLP-1 drug demand and strategic Citius Oncology distribution deal, reinforcing growth in specialty pharma.
Cencora Q3 2025 Earnings Analysis: Specialty Pharma Growth Amid Margin Pressures
Explore Cencora's Q3 2025 earnings drivers, highlighting specialty pharma growth, GLP-1 impact, margin pressures, and strategic positioning in pharma distribution.
Cencora (COR) Q3 2025 Earnings Beat Highlights Specialty Pharma Growth
Cencora (COR) delivered a strong Q3 2025 earnings beat, driven by specialty pharma and GLP-1 demand, raising FY25 EPS guidance amid robust revenue growth.
Cencora (COR) Q3 Earnings, GLP‑1 Growth & Valuation Signals
Data-driven update: Cencora’s Q3 beat, GLP‑1 contribution, RCA accretion, WBA concentration and how forward multiples price specialty execution.
Cencora (COR) — Earnings Beats, Buybacks & Balance‑Sheet Repair
Data-driven update on Cencora: revenue expansion to $293.96B, narrower margins, heavy buybacks and FCF trends reshaping capital allocation and dividend sustainability.
Cencora (COR): Q3 Beat, GLP‑1 Momentum and the Walgreens Overhang
Cencora reported strong Q3 revenue and EPS beats driven by specialty/GLP‑1s, but leverage, valuation dispersion and the WBA stake remain material overhangs.
Cencora (COR): Rich Multiples vs. Tight Margins — The Numeric Trade-Off
Cencora trades at **~29.8x P/E** on thin operating margins and a complex customer footprint; our recalculation surfaces material ratio conflicts and scenario levers investors should watch.
Cencora (COR): Premium Valuation Meets Specialty Drug Momentum — What the Numbers Reveal
Cencora reports sustained GLP-1 and specialty strength and a string of earnings beats while trading at **$293.48** with a **trailing P/E ~30.13**; margin and balance-sheet quirks raise execution questions.
Cencora (COR) — Margin Transition and Cash-Flow Resilience
Cencora posted **+12.13%** revenue growth in FY2024 while net income fell **-13.71%**, highlighting a mix-driven margin story, strong cash conversion and a governance-led pivot under new leadership.